You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethohexital
Accession NumberDB00474  (APRD00058)
TypeSmall Molecule
GroupsApproved
DescriptionAn intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. [PubChem]
Structure
Thumb
Synonyms
(+-)-5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid
5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione
5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid
alpha-DL-1-Methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid
Methohexital
Methohexitalum
Methohexitone
Metohexital
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Brevital SodiumInjection, powder, lyophilized, for solution500 mg/1Intramuscular; Intravenous; RectalPar Pharmaceutical, Inc.2007-11-01Not applicableUs
Brevital SodiumInjection, powder, lyophilized, for solution2.5 g/1Intramuscular; Intravenous; RectalPar Pharmaceutical, Inc.2007-11-01Not applicableUs
Brevital SodiumInjection, powder, lyophilized, for solution500 mg/1Intramuscular; Intravenous; RectalA S Medication Solutions Llc2007-11-01Not applicableUs
Brietal Sodium Ampoule 660Powder, for solution500 mgIntravenousEli Lilly Canada Inc1960-12-312000-08-03Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BrevitalNot Available
BrietalNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Methohexital sodium
Thumb
  • InChI Key: KDXZREBVGAGZHS-UHFFFAOYNA-M
  • Monoisotopic Mass: 284.113687095
  • Average Mass: 284.2861
DBSALT000631
Categories
UNIIE5B8ND5IPE
CAS number151-83-7
WeightAverage: 262.3043
Monoisotopic: 262.131742452
Chemical FormulaC14H18N2O3
InChI KeyNZXKDOXHBHYTKP-UHFFFAOYSA-N
InChI
InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)
IUPAC Name
5-(hex-3-yn-2-yl)-1-methyl-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione
SMILES
CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O
Pharmacology
IndicationMethohexital is indicated for use as an intravenous anaesthetic. It has also been commonly used to induce deep sedation.
Structured Indications Not Available
PharmacodynamicsMethohexital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Mechanism of actionMethohexital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
antagonist
HumanP14867 details
Related Articles
AbsorptionThe absolute bioavailability following rectal administration of methohexital is 17%.
Volume of distributionNot Available
Protein binding73%
Metabolism

Metabolism occurs in the liver through demethylation and oxidation. Side-chain oxidation is the most important biotransformation involved in termination of biologic activity.

Route of eliminationExcretion occurs via the kidneys through glomerular filtration.
Half life5.6 ± 2.7 minutes
ClearanceNot Available
ToxicityThe onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Methohexital is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Methohexital is combined with 7-Nitroindazole.Experimental
AcebutololMethohexital may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Methohexital.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Methohexital.Approved
AcetazolamideMethohexital may increase the hypotensive activities of Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Methohexital is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Methohexital is combined with Agomelatine.Approved, Investigational
AldesleukinMethohexital may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Methohexital is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Methohexital is combined with Alfentanil.Approved, Illicit
AliskirenMethohexital may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methohexital is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methohexital.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Methohexital.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Methohexital.Experimental
AmifostineMethohexital may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideMethohexital may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Methohexital.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Methohexital.Approved
AmiodaroneMethohexital may increase the hypotensive activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Methohexital is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Methohexital.Approved
AmlodipineMethohexital may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Methohexital is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Methohexital is combined with Amperozide.Experimental
Amphotericin BMethohexital may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmrinoneThe metabolism of Amrinone can be increased when combined with Methohexital.Approved
Amyl NitriteMethohexital may increase the hypotensive activities of Amyl Nitrite.Approved
Aop200704The serum concentration of Aop200704 can be decreased when it is combined with Methohexital.Investigational
ApomorphineMethohexital may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineMethohexital may increase the hypotensive activities of Apraclonidine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Methohexital is combined with Aripiprazole.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Methohexital.Approved
Arsenic trioxideMethohexital may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Methohexital is combined with Asenapine.Approved
AtenololMethohexital may increase the hypotensive activities of Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Azaperone.Vet Approved
AzelastineMethohexital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Methohexital is combined with Azelastine.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Methohexital.Approved
Azilsartan medoxomilMethohexital may increase the hypotensive activities of Azilsartan medoxomil.Approved
AzimilideThe metabolism of Azimilide can be increased when combined with Methohexital.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Methohexital is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Barbital.Illicit
BarnidipineThe metabolism of Barnidipine can be increased when combined with Methohexital.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Methohexital.Experimental
BenazeprilMethohexital may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideMethohexital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Methohexital.Approved
BenperidolThe risk or severity of adverse effects can be increased when Methohexital is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methohexital is combined with Benzyl alcohol.Approved
BepridilThe metabolism of Bepridil can be increased when combined with Methohexital.Approved, Withdrawn
BetaxololMethohexital may increase the hypotensive activities of Betaxolol.Approved
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Methohexital.Approved
BisoprololMethohexital may increase the hypotensive activities of Bisoprolol.Approved
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Methohexital.Approved
BortezomibMethohexital may increase the hypotensive activities of Bortezomib.Approved, Investigational
BretyliumMethohexital may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methohexital is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
BromazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Bromazepam.Approved, Illicit
BromocriptineMethohexital may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Methohexital is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Methohexital is combined with Brotizolam.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Methohexital.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Methohexital.Experimental, Investigational
BumetanideMethohexital may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methohexital.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Methohexital.Approved
BuprenorphineMethohexital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Methohexital is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methohexital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Methohexital is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Methohexital is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Methohexital is combined with Butorphanol.Approved, Illicit, Vet Approved
CaiThe metabolism of Cai can be increased when combined with Methohexital.Investigational
CanagliflozinMethohexital may increase the hypotensive activities of Canagliflozin.Approved
CandesartanMethohexital may increase the hypotensive activities of Candesartan.Approved
CaptoprilMethohexital may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Methohexital is combined with Carbamazepine.Approved, Investigational
CarbetocinMethohexital may increase the hypotensive activities of Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Methohexital is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Methohexital is combined with Carisoprodol.Approved
CarteololMethohexital may increase the hypotensive activities of Carteolol.Approved
CarvedilolMethohexital may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Methohexital.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Methohexital is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Methohexital is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Methohexital can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Chloroprocaine.Approved
ChlorothiazideMethohexital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Methohexital.Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneMethohexital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorzoxazone.Approved
CilazaprilMethohexital may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Methohexital.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Methohexital.Approved
CitalopramThe risk or severity of adverse effects can be increased when Methohexital is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Methohexital is combined with Clemastine.Approved
ClevidipineMethohexital may increase the hypotensive activities of Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Methohexital is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Methohexital is combined with Clobazam.Approved, Illicit
ClofarabineMethohexital may increase the hypotensive activities of Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Methohexital is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Methohexital.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Methohexital is combined with Clorazepate.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methohexital.Approved
CocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methohexital.Approved, Illicit
ConivaptanMethohexital may increase the hypotensive activities of Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe therapeutic efficacy of Conjugated Equine Estrogens can be decreased when used in combination with Methohexital.Approved
CyclizineThe risk or severity of adverse effects can be increased when Methohexital is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Methohexital.Approved
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Methohexital.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Methohexital is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Methohexital is combined with Dantrolene.Approved
DapagliflozinMethohexital may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methohexital.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dapoxetine.Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Methohexital.Experimental
deramciclaneThe risk or severity of adverse effects can be increased when Methohexital is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Methohexital is combined with Desflurane.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Methohexital.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Methohexital is combined with Desloratadine.Approved, Investigational
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Methohexital.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methohexital is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Methohexital is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Methohexital is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenamideMethohexital may increase the hypotensive activities of Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Methohexital.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Methohexital.Approved
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Methohexital.Approved
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Methohexital.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Methohexital is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydromorphine.Experimental, Illicit
DiltiazemMethohexital may increase the hypotensive activities of Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Methohexital is combined with Dimenhydrinate.Approved
DinutuximabMethohexital may increase the hypotensive activities of Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Methohexital is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Methohexital is combined with Diphenoxylate.Approved, Illicit
DipyridamoleMethohexital may increase the hypotensive activities of Dipyridamole.Approved
DoramectinThe risk or severity of adverse effects can be increased when Methohexital is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Methohexital.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Methohexital.Investigational
DoxazosinMethohexital may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Methohexital.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Methohexital.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Methohexital is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Methohexital.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Methohexital is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Methohexital is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dyclonine.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Methohexital.Approved
EcgonineThe risk or severity of adverse effects can be increased when Methohexital is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Methohexital is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Methohexital is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Methohexital is combined with Efavirenz.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be increased when combined with Methohexital.Approved
EmpagliflozinMethohexital may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilMethohexital may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatMethohexital may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methohexital.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Methohexital is combined with Entacapone.Approved, Investigational
EperisoneThe metabolism of Eperisone can be increased when combined with Methohexital.Approved, Investigational
EplerenoneMethohexital may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolMethohexital may increase the hypotensive activities of Epoprostenol.Approved
EprosartanMethohexital may increase the hypotensive activities of Eprosartan.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Methohexital is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Methohexital.Investigational
EsmololMethohexital may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Methohexital is combined with Estazolam.Approved, Illicit
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Methohexital.Approved, Investigational, Vet Approved
EstramustineThe therapeutic efficacy of Estramustine can be decreased when used in combination with Methohexital.Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Methohexital.Approved
Estrone sulfateThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Methohexital.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methohexital.Approved
Etacrynic acidMethohexital may increase the hypotensive activities of Etacrynic acid.Approved
EthanolMethohexital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methohexital.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Methohexital.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethotoin.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Methohexital.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Methohexital.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Methohexital is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Methohexital is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methohexital.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Methohexital.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Methohexital is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Methohexital is combined with Ezogabine.Approved
FelbamateThe serum concentration of Methohexital can be increased when it is combined with Felbamate.Approved
FelodipineMethohexital may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Methohexital.Withdrawn
FenoldopamMethohexital may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Methohexital is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Methohexital is combined with Fexofenadine.Approved
FimasartanMethohexital may increase the hypotensive activities of Fimasartan.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Methohexital is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Fludiazepam.Approved, Illicit
FluindioneThe metabolism of Fluindione can be increased when combined with Methohexital.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Methohexital is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Methohexital is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Methohexital.Approved, Investigational
FosinoprilMethohexital may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Methohexital is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Methohexital is combined with Fospropofol.Approved, Illicit
FurosemideMethohexital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Methohexital is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methohexital is combined with gabapentin enacarbil.Approved
GallopamilThe metabolism of Gallopamil can be increased when combined with Methohexital.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Methohexital is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Methohexital is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Methohexital.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Methohexital is combined with Glutethimide.Approved, Illicit
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Methohexital.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Methohexital is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Methohexital is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Methohexital is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Methohexital is combined with Heroin.Approved, Illicit
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Methohexital.Withdrawn
HexobarbitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Hexobarbital.Approved
HydralazineMethohexital may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideMethohexital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneMethohexital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideMethohexital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methohexital.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Iloperidone.Approved
IloprostMethohexital may increase the hypotensive activities of Iloprost.Approved, Investigational
ImidaprilMethohexital may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Methohexital.Approved
IndalpineThe risk or severity of adverse effects can be increased when Methohexital is combined with Indalpine.Investigational, Withdrawn
IndapamideMethohexital may increase the orthostatic hypotensive activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Methohexital.Withdrawn
IndoraminMethohexital may increase the hypotensive activities of Indoramin.Withdrawn
IrbesartanMethohexital may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidMethohexital may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Methohexital is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateMethohexital may increase the hypotensive activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateMethohexital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineMethohexital may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineMethohexital may increase the hypotensive activities of Isradipine.Approved
KetamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketobemidone.Approved
LabetalolMethohexital may increase the hypotensive activities of Labetalol.Approved
LacidipineThe metabolism of Lacidipine can be increased when combined with Methohexital.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Methohexital.Approved, Investigational
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Methohexital.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Methohexital is combined with Levetiracetam.Approved, Investigational
LevobunololMethohexital may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Methohexital is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Methohexital is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Methohexital is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methohexital is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Methohexital is combined with Levomilnacipran.Approved
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Methohexital.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Methohexital is combined with Levorphanol.Approved
LevosimendanMethohexital may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methohexital.Approved, Vet Approved
LisinoprilMethohexital may increase the hypotensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Methohexital is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Methohexital is combined with Lofentanil.Illicit
LofexidineMethohexital may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoratadineThe risk or severity of adverse effects can be increased when Methohexital is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methohexital.Approved
LosartanMethohexital may increase the hypotensive activities of Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methohexital.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Methohexital is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Lurasidone.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Methohexital.Investigational
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved, Vet Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Methohexital.Approved
MannitolMethohexital may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Methohexital is combined with Maprotiline.Approved
MecamylamineMethohexital may increase the hypotensive activities of Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Methohexital is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Methohexital.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Methohexital is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methohexital.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Mesoridazine.Approved
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Methohexital.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Methohexital is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methohexital.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methohexital is combined with Methadyl Acetate.Approved, Illicit
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Methohexital.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Methohexital is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Methaqualone.Illicit, Withdrawn
MethazolamideMethohexital may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methohexital is combined with Methocarbamol.Approved, Vet Approved
MethotrimeprazineMethohexital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methohexital is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methohexital is combined with Methsuximide.Approved
MethyclothiazideMethohexital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaMethohexital may increase the hypotensive activities of Methyldopa.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methylphenobarbital.Approved
MetipranololMethohexital may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMethohexital may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololMethohexital may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineMethohexital may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MibefradilThe metabolism of Mibefradil can be increased when combined with Methohexital.Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Methohexital is combined with Midazolam.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Methohexital is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved, Investigational
MinoxidilMethohexital may increase the hypotensive activities of Minoxidil.Approved
MirtazapineMethohexital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoexiprilMethohexital may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methohexital.Approved, Investigational
MoxonidineMethohexital may increase the hypotensive activities of Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved, Investigational
NadololMethohexital may increase the hypotensive activities of Nadolol.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Methohexital.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Methohexital is combined with Nalbuphine.Approved
NebivololMethohexital may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Nefazodone.Approved, Withdrawn
NesiritideMethohexital may increase the hypotensive activities of Nesiritide.Approved, Investigational
NicardipineMethohexital may increase the hypotensive activities of Nicardipine.Approved
NifedipineMethohexital may increase the hypotensive activities of Nifedipine.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Methohexital.Experimental
NiludipineThe metabolism of Niludipine can be increased when combined with Methohexital.Experimental
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Methohexital.Approved
NimesulideThe metabolism of Nimesulide can be increased when combined with Methohexital.Approved, Withdrawn
NimodipineMethohexital may increase the hypotensive activities of Nimodipine.Approved
NisoldipineMethohexital may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Nitrazepam.Approved
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Methohexital.Approved
Nitric OxideMethohexital may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinMethohexital may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideMethohexital may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Methohexital is combined with Nitrous oxide.Approved, Vet Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Methohexital.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Methohexital.Approved
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Methohexital.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Methohexital.Approved
ObinutuzumabMethohexital may increase the hypotensive activities of Obinutuzumab.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methohexital.Approved, Investigational
OlmesartanMethohexital may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Methohexital is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Methohexital is combined with Ondansetron.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Methohexital.Investigational
OpiumThe risk or severity of adverse effects can be increased when Methohexital is combined with Opium.Approved, Illicit
OrphenadrineMethohexital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Methohexital is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelMethohexital may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Paliperidone.Approved
PapaverineMethohexital may increase the hypotensive activities of Papaverine.Approved
ParaldehydeMethohexital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Methohexital is combined with Paroxetine.Approved, Investigational
PenbutololMethohexital may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Methohexital is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methohexital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
PerazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Perazine.Investigational
PerhexilineThe metabolism of Perhexiline can be increased when combined with Methohexital.Approved
PerindoprilMethohexital may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Methohexital is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Perphenazine.Approved
PethidineMethohexital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenelzineMethohexital may increase the hypotensive activities of Phenelzine.Approved
PhenindioneThe metabolism of Phenindione can be increased when combined with Methohexital.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Phenobarbital.Approved
PhenoxybenzamineMethohexital may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methohexital is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Methohexital.Approved
PhentolamineMethohexital may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Methohexital is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Methohexital is combined with Pimozide.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Methohexital.Approved
PindololMethohexital may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Methohexital is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Methohexital is combined with Pizotifen.Approved
PolythiazideMethohexital may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Methohexital is combined with Pomalidomide.Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Methohexital.Approved
PramipexoleMethohexital may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Prazepam.Approved, Illicit
PrazosinMethohexital may increase the hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methohexital.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Methohexital is combined with Pregnanolone.Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Methohexital.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Methohexital.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methohexital.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methohexital.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Promethazine.Approved
PropacetamolThe metabolism of Propacetamol can be increased when combined with Methohexital.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Methohexital is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Propoxycaine.Approved
PropranololMethohexital may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Methohexital.Approved
PSD502The risk or severity of adverse effects can be increased when Methohexital is combined with PSD502.Investigational
PyridoxineThe metabolism of Methohexital can be increased when combined with Pyridoxine.Approved, Nutraceutical, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Methohexital is combined with Quetiapine.Approved
QuinaprilMethohexital may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneMethohexital may increase the orthostatic hypotensive activities of Quinethazone.Approved
RacloprideThe risk or severity of adverse effects can be increased when Methohexital is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Methohexital is combined with Ramelteon.Approved, Investigational
RamiprilMethohexital may increase the hypotensive activities of Ramipril.Approved
RasagilineMethohexital may increase the hypotensive activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Methohexital is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methohexital.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methohexital.Approved
RifabutinThe metabolism of Methohexital can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Methohexital can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Methohexital can be increased when combined with Rifapentine.Approved
RiociguatMethohexital may increase the hypotensive activities of Riociguat.Approved
RisedronateThe metabolism of Risedronate can be increased when combined with Methohexital.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Methohexital is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Romifidine.Vet Approved
RopiniroleMethohexital may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methohexital.Approved
RotigotineMethohexital may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methohexital.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Methohexital is combined with S-Ethylisothiourea.Experimental
SacubitrilMethohexital may increase the hypotensive activities of Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Methohexital is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methohexital.Approved, Vet Approved
SelegilineMethohexital may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Methohexital is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Methohexital is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Methohexital is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteMethohexital may increase the hypotensive activities of Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Methohexital.Approved
SotalolMethohexital may increase the hypotensive activities of Sotalol.Approved
SpironolactoneMethohexital may increase the hypotensive activities of Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Methohexital is combined with Stiripentol.Approved
StreptokinaseMethohexital may increase the hypotensive activities of Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Methohexital is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methohexital.Approved
SuvorexantMethohexital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Methohexital.Approved
TamsulosinMethohexital may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Methohexital is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Methohexital is combined with Tasimelteon.Approved
TelmisartanMethohexital may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methohexital.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Methohexital.Approved
TerazosinMethohexital may increase the hypotensive activities of Terazosin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetrodotoxin.Investigational
ThalidomideMethohexital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Methohexital.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Methohexital is combined with Tiagabine.Approved
TianeptineThe metabolism of Tianeptine can be increased when combined with Methohexital.Approved
TiaprideThe risk or severity of adverse effects can be increased when Methohexital is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Tiletamine.Vet Approved
TimololMethohexital may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Tizanidine.Approved
TolazolineMethohexital may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Methohexital is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Methohexital.Approved
TopiramateThe risk or severity of adverse effects can be increased when Methohexital is combined with Topiramate.Approved
TorasemideMethohexital may increase the hypotensive activities of Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methohexital.Approved, Investigational
TrandolaprilMethohexital may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Methohexital.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Methohexital is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Trazodone.Approved, Investigational
TretinoinMethohexital may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneMethohexital may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Methohexital is combined with Triazolam.Approved
TrichlormethiazideMethohexital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Methohexital.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Methohexital is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Methohexital.Approved
Valproic AcidThe serum concentration of Methohexital can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanMethohexital may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Methohexital is combined with Venlafaxine.Approved
VerapamilMethohexital may increase the hypotensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Methohexital is combined with Vigabatrin.Approved
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Methohexital.Investigational
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Methohexital.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Methohexital is combined with Vortioxetine.Approved
WarfarinThe metabolism of Warfarin can be increased when combined with Methohexital.Approved
XylazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Xylazine.Vet Approved
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Methohexital.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Methohexital is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Methohexital is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methohexital.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Zolazepam.Vet Approved
ZolpidemMethohexital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Methohexital is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Methohexital is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Methohexital is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Methohexital is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN01AF01N05CA15
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (184 KB)
MSDSDownload (46.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9143
Blood Brain Barrier+0.982
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.6307
P-glycoprotein inhibitor IInhibitor0.5661
P-glycoprotein inhibitor IINon-inhibitor0.9294
Renal organic cation transporterNon-inhibitor0.9297
CYP450 2C9 substrateNon-substrate0.823
CYP450 2D6 substrateNon-substrate0.8823
CYP450 3A4 substrateNon-substrate0.6454
CYP450 1A2 substrateNon-inhibitor0.8001
CYP450 2C9 inhibitorNon-inhibitor0.8179
CYP450 2D6 inhibitorNon-inhibitor0.9099
CYP450 2C19 inhibitorNon-inhibitor0.7836
CYP450 3A4 inhibitorNon-inhibitor0.8501
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.954
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8264
BiodegradationNot ready biodegradable0.9737
Rat acute toxicity2.9098 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.978
hERG inhibition (predictor II)Non-inhibitor0.9697
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Jhp pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous; Rectal2.5 g/1
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous; Rectal500 mg/1
Powder, for solutionIntravenous500 mg
Prices
Unit descriptionCostUnit
Brevital sodium 2.5 gm vial221.2USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0524 mg/mLALOGPS
logP2.43ALOGPS
logP2.29ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)8.73ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area66.48 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity71.51 m3·mol-1ChemAxon
Polarizability27.4 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (12.5 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0fbc-9520000000-5141cdceea7f6d5013b0View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Koltchine VV, Ye Q, Finn SE, Harrison NL: Chimeric GABAA/glycine receptors: expression and barbiturate pharmacology. Neuropharmacology. 1996;35(9-10):1445-56. [PubMed:9014160 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23